Table 2.
Clinical features between uterus adenosarcoma patients in lymph node dissection and non-dissection group.
| Variables | All n = 1027(%) |
Lymph node dissection | ||
|---|---|---|---|---|
| Yes (n = 545[53.1%]) |
No (n = 482[46.9%]) |
P value | ||
| Age (yr) | 0.610 | |||
| Median | 56 | 57 | 55.5 | |
| Range (IQR) | 46–67 | 47–66 | 46–67 | |
| Age at diagnosis (yr) | 0.277 | |||
| <56 | 495 (48.2%) | 254 (46.6%) | 241 (50.0%) | |
| ≥56 | 532 (51.8%) | 291 (53.4%) | 241 (50.0%) | |
| Marital status | 0.037 | |||
| Yes | 511 (49.8%) | 291 (53.4%) | 220 (45.6%) | |
| No | 469 (45.7%) | 233 (42.8%) | 236 (49.0%) | |
| Unknown | 47 (4.6%) | 21 (3.9%) | 26 (5.4%) | |
| Race | 0.619 | |||
| White | 783 (76.2%) | 417 (76.5%) | 366 (75.9%) | |
| Black | 126 (12.3%) | 61 (11.2%) | 65 (13.5%) | |
| Other* | 113 (11.0%) | 64 (11.7%) | 49 (10.2%) | |
| Unknown | 5 (0.5%) | 3 (0.6%) | 2 (0.4%) | |
| Multiple lesions | 0.771 | |||
| Yes | 226 (22.0%) | 118 (21.7%) | 108 (22.4%) | |
| No | 801 (78.0%) | 427 (78.3%) | 374 (77.6%) | |
| Tumor size | 0.030 | |||
| Present | 666 (64.8%) | 370 (67.9%) | 296 (61.4%) | |
| Missing† | 361 (35.2%) | 175 (32.1%) | 186 (38.6%) | |
| Largest tumor size (mm) | 0.685 | |||
| ≤48 | 271 (40.7%) | 148 (40%) | 123 (41.6%) | |
| >48 | 395 (59.3%) | 222 (60%) | 173 (58.4%) | |
| Grade | 0.059 | |||
| Grade I | 127 (12.4%) | 56 (10.3%) | 71 (14.7%) | |
| Grade II | 190 (18.5%) | 99 (18.2%) | 91 (18.9%) | |
| Grade III | 58 (5.6%) | 35 (6.4%) | 23 (4.8%) | |
| Grade IV | 139 (13.5%) | 85 (15.6%) | 54 (11.2%) | |
| Unknown | 513 (50.0%) | 270 (49.5%) | 243 (50.4%) | |
| T stage | 0.927 | |||
| T1 | 314 (30.6%) | 164 (30.1%) | 150 (31.1%) | |
| T2 | 19 (1.9%) | 10 (1.8%) | 9 (1.9%) | |
| T3 | 10 (1.0%) | 4 (0.7%) | 6 (1.2%) | |
| T4 | 2 (0.2%) | 1 (0.2%) | 1 (0.2%) | |
| Tx | 682 (66.4%) | 366 (67.2%) | 316 (65.6%) | |
| Lymph node status | - | |||
| Positive | 19 (3.5%) | 19 (3.5%) | 0 | |
| Negative | 509 (93.4%) | 509 (93.4%) | 0 | |
| Unknown | 17 (3.1%) | 17 (3.1%) | 0 | |
| Radiotherapy | <0.001 | |||
| Yes | 176 (17.1%) | 125 (22.9%) | 51 (10.6%) | |
| No | 851 (82.9%) | 420 (77.1%) | 431 (89.4%) | |
| Radiotherapy sequence | <0.001 | |||
| Prior surgery | 6 (3.4%) | 4 (3.2%) | 2 (3.9%) | |
| Prior and after surgery | 3 (1.7%) | 2 (1.6%) | 1 (2.0%) | |
| After surgery | 167 (94.9%) | 119 (95.2%) | 48 (94.1%) | |
| Chemotherapy | 0.007 | |||
| Yes | 126 (12.3%) | 81 (14.9%) | 45 (9.3%) | |
| No | 901 (87.7%) | 464 (85.1%) | 437 (90.7%) | |
| Follow-up time (mo) | 0.014 | |||
| Median | 58 | 64 | 49.5 | |
| Range (IQR) | 20–113 | 22.5–118 | 18–106.25 | |
IQR = interquartile range.
*
Others: American Indian/AK Native, Asian/Pacific Islander.
†
Missing: excluded in the survival analysis.